Von Hippel-Lindau Disease Clinical Trials

9 recruiting

Von Hippel-Lindau Disease Trials at a Glance

9 actively recruiting trials for von hippel-lindau disease are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Milan, Tel Aviv, and Bethesda. Lead sponsors running von hippel-lindau disease studies include Merck Sharp & Dohme LLC, IRCCS San Raffaele, and Hospital Italiano de Buenos Aires.

Browse von hippel-lindau disease trials by phase

Treatments under study

About Von Hippel-Lindau Disease Clinical Trials

Looking for clinical trials for Von Hippel-Lindau Disease? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Von Hippel-Lindau Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Von Hippel-Lindau Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting
Phase 3

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Carcinoma, Renal CellVon Hippel-Lindau Disease
Merck Sharp & Dohme LLC450 enrolled9 locationsNCT07405164
Recruiting
Phase 2

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Neuroendocrine TumorsVon Hippel-Lindau DiseaseVHL Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)740 enrolled1 locationNCT04074135
Recruiting

Institutional Registry of Rare Diseases

ParagangliomaPheochromocytomaAmyloidosis+23 more
Hospital Italiano de Buenos Aires380 enrolled1 locationNCT06573723
Recruiting

Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients

Neuroendocrine NeoplasmParagangliomaPheochromocytoma+23 more
Universidad Nacional Autonoma de Mexico750 enrolled3 locationsNCT06523582
Recruiting

MyVHL: Patient Natural History Study

Von Hippel-Lindau DiseaseHereditary Leiomyomatosis and Renal Cell CancerBirt-Hogg-Dube Syndrome+1 more
Joshua Mann, MPH10,000 enrolled1 locationNCT03749980
Recruiting

Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells

Carcinoma, Renal CellVon Hippel-Lindau Disease
IRCCS San Raffaele50 enrolled1 locationNCT06194669
Recruiting
Not Applicable

Propranolol and Von Hippel-Lindau Disease

Von Hippel-Lindau DiseaseHemangioblastoma of CNS
Assistance Publique - Hôpitaux de Paris85 enrolled1 locationNCT05424016
Recruiting

Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients

Von Hippel-Lindau Disease
Marie Luise Bisgaard, MD380 enrolled1 locationNCT02420067